US Pharma MarketingThe post Innate Pharma concludes enrolment in dose escalation of IPH4502 study appeared first on Clinical Trials Arena.
Innate Pharma concludes enrolment in dose escalation of IPH4502 study
Innate Pharma has completed patient enrolment in the dose escalation segment of the Phase I IPH4502-101 study, involving its Nectin-4 exatecan ADC, IPH4502. The post Innate Pharma concludes enrolment in dose escalation of IPH4502 study appeared first on Clinical Trials Arena .
Innate Pharma has completed patient enrolment in the dose escalation segment of the Phase I IPH4502-101 study, involving its Nectin-4 exatecan ADC, IPH4502.
Source: Clinical Trials Arena